ArticleTranslational cancer research2026
The potential of ATF5 as a prognostic marker and therapeutic target in cancer: insights from bioinformatics analysis and experimental validation.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Activating transcription factor 5 (ATF5) is a transcription regulator closely associated with cancers. Our previous studies have identified the expression and function of ATF5 in various malignant tumors. However, a comprehensive study of ATF5 remains lacking across different tumor types. This study will focus on a comprehensive analysis of ATF5 across various cancers, while further investigating the function of the ATF5 protein in gliomas and its protein characteristics. Methods: We investigated ATF5 expression across various tumors using systematic bioinformatics analysis. We further examined the correlations between ATF5 expression and patient prognosis, tumor staging, and immunological characteristics. Additionally, functional enrichment analysis was performed on proteins interacting with or co-expressed with ATF5. We employed flow cytometry to analyze apoptosis and investigate the function of ATF5 in glioma cell lines. Furthermore, immunohistochemistry (IHC) was employed to validate the relationship between ATF5 expression and distinct glioma grades. Finally, we explored the protein phase-separation capacity of ATF5 and its influencing factors Results: ATF5 expression levels exhibited a strong correlation with prognosis in multiple cancers. Functional clustering analysis of the proteins interacting with ATF5 and co-expressed with ATF5 suggested that ATF5 might influence tumor cell proliferation, differentiation, and apoptosis. Immunohistochemical results demonstrated a strong association between ATF5 expression and glioma pathological grades. Additionally, flow cytometry analysis showed that interfering with ATF5 expression using small interfering RNA (siRNA) promoted apoptosis in glioma cells. Interestingly, droplet formation experiments confirmed that ATF5 is capable of aggregation Conclusions: Our findings indicate that ATF5 has prognostic value in cancer treatment, providing a potential therapeutic target for subsequent treatment of related cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.